Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Emily Buxton"'
Autor:
Christian H. Ottensmeier, Freda K. Stevenson, Gareth J. Thomas, Ugur Sahin, Petra Simon, Toni Weinschenk, Duncan I. Jodrell, Alan Anthoney, Sally Clive, Ann O'Callaghan, Andrew Bateman, Sarah Halford, Ceri Edwards, Emily Buxton, Paul Lloyd-Evans, Andrew King, Stephen M. Thirdborough, Jana Stasakova, Lindsey Chudley, Angelica Cazaly, Ann Mander, Katy J. McCann
Purpose: We have clinically evaluated a DNA fusion vaccine to target the HLA-A*0201–binding peptide CAP-1 from carcinoembryonic antigen (CEA605–613) linked to an immunostimulatory domain (DOM) from fragment C of tetanus toxin.Experimental Design:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4202489da8884143afe28a39cda33e82
https://doi.org/10.1158/1078-0432.c.6524756.v1
https://doi.org/10.1158/1078-0432.c.6524756.v1
Autor:
Petra Simon, Paul Lloyd-Evans, Emily Buxton, Stephen M. Thirdborough, Sarah Halford, Angelica Cazaly, Toni Weinschenk, Ann Mander, Jana Stasakova, Christian H. Ottensmeier, Alan Anthoney, Sally Clive, Ann O'Callaghan, Gareth J. Thomas, Andy King, Duncan I. Jodrell, Ceri Edwards, Freda K. Stevenson, Lindsey Chudley, Ugur Sahin, Andrew Bateman, Katy J. McCann
Purpose: We have clinically evaluated a DNA fusion vaccine to target the HLA-A*0201–binding peptide CAP-1 from carcinoembryonic antigen (CEA605–613) linked to an immunostimulatory domain (DOM) from fragment C of tetanus toxin. Experimental Design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e19df3dd255024ee73f22d958e0fe227
Autor:
Sarah Halford, Simon P. Joel, Andrea Rockall, Chris Twelves, Amanda D. Race, Andrew Scarsbrook, Paul M. Loadman, Nicola Dobbs, Daniel M. Berney, Iain A. McNeish, Alan Anthoney, Angela Patikis, Mohammed Ikram, Emily Buxton
Publikováno v:
Journal of Clinical Oncology. 31:2525-2525
2525 Background: GSK1070916A is a potent and selective inhibitor of Aurora B and C. This phase I study in collaboration with GlaxoSmithKline was part of the Cancer Research UK Clinical Development Programme. Methods: Patients (pts) with advanced/meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3fca7cb28e6ccab96dd1f8bea02db0cc
https://doi.org/10.1200/jco.2013.31.15_suppl.2525
https://doi.org/10.1200/jco.2013.31.15_suppl.2525
